Treatment of Radiation and Cisplatin Induced Toxicities With Tempol
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities
associated with cisplatin and radiation treatment in head and neck cancer patients. Over the
course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and
assessed.